Husser, Oliver and Nunez, Julio and Nunez, Eduardo and Holzamer, Andreas and Camboni, Daniele and Luchner, Andreas and Sanchis, Juan and Bodi, Vicente and Riegger, Guenter A. J. and Schmid, Christof and Hilker, Michael and Hengstenberg, Christian (2013) Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation. JACC-CARDIOVASCULAR INTERVENTIONS, 6 (5). pp. 487-496. ISSN 1936-8798, 1876-7605
Full text not available from this repository. (Request a copy)Abstract
Objectives This study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]). Background Risk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need. Methods CA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transformation and dichotomized by its median value (M1 <= 15.7 U/ml vs. M2 > 15.7 U/ml). Results At a median follow-up of 183 days (interquartile range: 63 to 365) and 144 days (interquartile range: 56 to 365), 50 patients (22%) died and 75 patients (33%) experienced MACE. A 3-fold increase in the rates for death and MACE was observed in patients above the median (M2 vs. M1) of CA125 (5.2 vs. 1.6 per 10 person-years and 8.3 vs. 3.3 per 10 person-years, respectively; p for both <0.001). In a multivariable analysis adjusted for logistic EuroSCORE, New York Heart Association functional class III/IV, and device success, baseline values of CA125 (M2 vs. M1) independently predicted death (hazard ratio [HR]: 2.18; 95% confidence interval [CI]: 1.11 to 4.26; p = 0.023) and MACE (HR: 1.77; 95% CI: 1.05 to 2.98; p = 0.031). In the longitudinal analysis, lnCA125 as a timevarying exposure, was highly associated with both endpoints: HR: 1.47; 95% CI: 1.01 to 2.14; p = 0.043 and HR: 2.26; 95% CI: 1.28 to 3.98; p = 0.005, for death and MACE, respectively. Conclusions Serum levels of CA125 before and after TAVI independently predict death and MACE. (C) 2013 by the American College of Cardiology Foundation
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE HEART-FAILURE; BRAIN NATRIURETIC PEPTIDE; HIGH-RISK PATIENTS; SERUM-LEVELS; STENOSIS; REPLACEMENT; SOCIETY; SURGERY; CA125; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Herz-, Thorax- und herznahe Gefäßchirurgie Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Apr 2020 07:26 |
| Last Modified: | 09 Apr 2020 07:26 |
| URI: | https://pred.uni-regensburg.de/id/eprint/16691 |
Actions (login required)
 |
View Item |
